Meet The Team
Our team of experts has extensive knowledge in product development and commercial launches in UK, Australia, and international markets. Ateria’s founders, Professor John Hunter and Dr Rosemary Waring remain on the Medical Advisory Board.
Leadership Team
Douglas Dundonald
CHAIRMAN
Douglas is a founder and director of UK-based technology commercialisation group Scientific Venture Partners Ltd which has built a portfolio of high potential technology-based companies arising from leading research institutions.
He has been involved in technology companies both as an investor and director for the last 20 years. He is also a former executive main board member of Anglo Pacific Group plc.
When an active member of the House of Lords, he held a position on the council of the Parliamentary Information Technology Committee.
He is the honorary consul for Chile in Scotland.
Rebecca Wilson
CHAIR
Rebecca is an experienced Non-Executive and Executive Director. She is currently Non-Executive Chair of digital health company Alcidion Limited (ASX ALC) and Advisory Board Chair of health and wellness marketplace Yo Life.
She has a deep knowledge and experience in corporate governance and advisory having worked almost exclusively with ASX companies over the last two decades. She’s developed a strong reputation in investor relations, risk and issues management.
She has played an integral role in fostering the intersection of health, technology and innovation with the investment community leading investor relations for more than 60 health-related companies through IPO. She is a Graduate of AICD.
Neil Wickers
NON-EXECUTIVE DIRECTOR
Neil is a successful CEO, leader and advisor with extensive experience in growing consumer goods and services businesses in both the UK and internationally.
Much of his career has been in the health foods sector and he has held senior positions at Unilever, including Senior Vice President for Culinary Foods.
There he grew the heart health brand Flora to be a leading grocery brand and launched the weight management brand Slim. Fast in Europe.
He has also worked in Private Equity backed businesses. As MD for PizzaExpress International, he built a high growth profitable restaurant business, including starting businesses in India and China.
Fred Edenius
EXECUTIVE DIRECTOR
Douglas is a founder and director of UK-based technology commercialisation group Scientific Venture Partners Ltd which has built a portfolio of high potential technology-based companies arising from leading research institutions.
He has been involved in technology companies both as an investor and director for the last 20 years. He is also a former executive main board member of Anglo Pacific Group plc.
When an active member of the House of Lords, he held a position on the council of the Parliamentary Information Technology Committee.
He is the honorary consul for Chile in Scotland.
Harry Karelis
EXECUTIVE DIRECTOR
Harry graduated from The University of Western Australia with Bachelors and Honours in Science majoring in Biochemistry and Microbiology as well as a Masters in Business Administration.
He is a Fellow of the Financial Services Institute of Australia, a Fellow of the Australian Institute of Company Directors and has qualified as a Chartered Financial Analyst (CFA). He has been involved in the Australian and international healthcare sector as a venture capital/private equity investor since 2000.
He has considerable experience working with early-stage technology companies particularly in the healthcare sector.
Steve Lydeamore
NON-EXECUTIVE DIRECTOR
Steve is currently CEO of Australian listed biopharmaceutical company Immuron, a
shareholder in Ateria Health Ltd.
He has 30 years international pharmaceutical experience, working in Australia, Canada and USA. Steve brings valuable international experience having spent eleven years working at Canadian global pharmaceutical company Apotex Inc., four years for Mayne Pharma (USA) Limited and three at Anatara Lifesciences Limited.
This includes extensive experience in finance, business development, sales and marketing, manufacturing, and research and development.
Medical Advisory Board
Prof. John Hunter
CLINICAL-CONSULTANT & FOUNDER
Professor Hunter is a Consultant Physician at Addenbrooke’s Hospital, Cambridge, visiting Professor of Medicine at the University of Cranfield and a recognised authority on diseases of the gut including Crohn’s Disease, Colitis and Irritable Bowel Syndrome.
He has contributed over 100 research papers to major medical journals including The Lancet, Nature and the British Medical Journal and is the author of several books on gut health.
Professor Hunter has been a consultant to a number of international companies and has been elected a Fellow of the American Gastroenterological Association and the American College of Gastroenterology.
Dr Rosemary Waring
SCIENTIFIC CONSULTANT & FOUNDER
Dr Waring is a graduate of Cambridge University and subsequently completed her PhD in Biochemistry at the University of Birmingham where she is now honorary Reader in Human Toxicology. She is a Fellow of the Royal College of Pathologists.
Dr Waring’s research is focused on the contribution of environmental factors to chronic ill-health and on the interactions of gut flora with gastrointestinal function. The research uses metabonomic and genomic techniques with in-depth analysis.
Dr Waring has published over 230 research papers and has served as an independent toxicologist on European Union (EFSA) and UK Government panels – Advisory Committee on Pesticides and Committee on Carcinogenicity.
Dr. Harry Frydenberg AM
CLINICAL CONSULTANT
Dr Frydenberg AM is a Fellow of the Royal Australian College of Surgeons and Director of the Epworth Centre for Bariatric Surgery in Melbourne, Australia.
Dr Frydenberg has more than 30 years’ experience performing a wide range of bariatric surgical procedures.
Dr Frydenberg was involved in the early organisation of Bariatric Surgeons in Australia (OSSANZ/ANZMOSS) and is a Past President and Honorary Life Member of the organisation.
Dr Frydenberg is also a Past President and Life Member of the IFSO (International Federation for the Surgery of Obesity and Metabolic Disorders) and the Founding President of the IFSO-Asia Pacific Chapter.
Advisory Board
Fiona Gately
FOOD INDUSTRY CONSULTANT
Fiona is a strategic adviser to food industry leaders with extensive knowledge of the food and drink industry and a wide network of contacts. Skilled at shaping complex, sometimes sensitive, campaigns to build profile and influence, drive government policy and engage partner networks.
Past roles include adviser to three Secretaries of State for the Environment, Food & Rural Affairs, campaign director for Jamie Oliver and brand development for HRH The Prince of Wales (organic movement and Duchy Originals).
Fiona is currently a non-executive board member of the Food Standards Agency in the UK.
Dr Nigel Davies
PRODUCTION CONSULTANT
Nigel is Director of Technical and Sustainability at Muntons plc, a UK based malting company and the largest producer of malted ingredients in the world.
An experienced Board level Director responsible for setting strategy and coaching, challenging and motivating a large team spanning Technical, Manufacturing, R&D, Quality, Safety, Health and Environmental compliance, Food Safety and Sustainability to achieve strategic goals.
Nigel has specific specialist skills in the global malt supply chain.
Mr David Stern
MARKETING CONSULTANT
David has a long and very successful career in consumer marketing and in particular digital marketing and e-commerce. He was most recently (2015-2020) the CEO of global consumer brand Crabtree & Evelyn where he was instrumental in the turnaround of the business and transitioned a traditional business to a digital business where he reduced overheads by 87% (£75m) and transformed the company resulting in 3%+ weekly growth and 70%+ gross margins.
He has specific expertise in business strategy, brand building and turnarounds,
digital transformation, social commerce & communication, process and product innovation, supply chain operations and geographic expansion.